No Data
No Data
Organon (OGN) Advances While Market Declines: Some Information for Investors
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
Barclays Maintains Organon & Co(OGN.US) With Buy Rating, Maintains Target Price $24
Express News | Reported Saturday, Organon's VTAMA Phase 3 Data Shows 84% Of Patients Maintained Mild Disease After 80-Day Off-Treatment Interval In Adults And Children 2+
Express News | May Health Appoints Seasoned Medtech Executive, Colby Holtshouse, as President and CEO
MAY HEALTH APPOINTS SEASONED MEDTECH EXECUTIVE, COLBY HOLTSHOUSE, AS PRESIDENT AND CEO